Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

10.020
-0.080-0.79%
Volume:2.08M
Turnover:20.50M
Market Cap:10.54B
PE:-27.07
High:10.020
Open:9.965
Low:9.515
Close:10.100
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.27
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-18.45%
ROA:-14.45%
PB:4.67
PE(LYR):-27.07
PS:4454.79

Loading ...

Ascletis’ ASC37 Triple Agonist Delivers 88% Greater Weight Loss Than Tirzepatide; Monthly Injection and Oral BLA Filings Planned for 2026

Bulletin Express
·
Jul 27

Ascletis Says ASC37 Triple Agonist Posts 88% Greater Weight Loss than Tirzepatide in Obese Mice

Reuters
·
Jul 27

Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation

Reuters
·
Jul 27

Ascletis Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation

Reuters
·
Jul 24

Ascletis Announces Oral Discussion of Asc36_35 Fdc Preclinical Data Demonstrating Superior Weight Loss to Eloralintide/tirzepatide Combination at the 62nd European Association for the Study of Diabetes (easd) Annual Meeting

THOMSON REUTERS
·
Jul 23

Ascletis Pharma Files HKEX Next-day Disclosure Return Reporting Share Repurchase for Cancellation

Reuters
·
Jul 20

ASCLETIS Executes Share Buyback, Spending HK$2.58 Million on July 17

Stock News
·
Jul 17

Ascletis Pharma Files HKEX Next-day Return Disclosing Share Repurchase for Cancellation

Reuters
·
Jul 17

Ascletis Advances First-in-Class Oral GLP-1R/GIPR Combo; IND Filing Planned for Q4 2026

Bulletin Express
·
Jul 15

Ascletis Selects Oral Glp-1/gip Fixed-dose Combo Asc30_48 for Clinical Development in Obesity

Reuters
·
Jul 15

Ascletis Pharma - Ind Submission to FDA for Asc30_48 Fdc Oral Tablets Expected in Q4 2026

THOMSON REUTERS
·
Jul 15

Ascletis Pharma - Asc30_48 Fdc Shows 52% Greater Body Weight Reduction vs Asc30 Monotherapy in Nhp Study

THOMSON REUTERS
·
Jul 15

ASCLETIS-B Chooses Fixed-Dose Combination of Pioneering Oral Small Molecule GIPR Agonist ASC48 and Oral GLP-1R Agonist ASC30 for Clinical Development

Stock News
·
Jul 15

Ascletis Pharma - Selects Fixed-dose Combination of Asc48 and Asc30 for Clinical Development

THOMSON REUTERS
·
Jul 15

Ascletis Accelerates Buyback: Acquires 0.20 Million Shares for HK$2.09 Million, Lifts 2026 Repurchase Total to 0.55 Million

Bulletin Express
·
Jul 14

ASCLETIS-B (01672) Allocates HK$2.09 Million for Share Buyback on July 14

Stock News
·
Jul 14

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jul 14

Biotech Stocks Surge as New National Essential Drug List Includes Innovative Therapies

Stock News
·
Jul 10

ASCLETIS-B Executes Share Buyback, Spending HK$1.119 Million

Stock News
·
Jul 08

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08